TRCT
ACLX

Tower Research Capital (TRC)’s Arcellx ACLX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Buy
2,270
+1,843
+432% +$163K 0.01% 1415
2025
Q4 		$27.8K Sell
427
-569
-57% -$45.4K ﹤0.01% 2856
2025
Q3 		$81.8K Sell
996
-5,147
-84% -$371K ﹤0.01% 2164
2025
Q2 		$405K Buy
6,143
+3,147
+105% +$196K 0.01% 1163
2025
Q1 		$197K Sell
2,996
-4,988
-62% -$338K 0.01% 1383
2024
Q4 		$612K Buy
7,984
+7,308
+1,081% +$631K 0.01% 924
2024
Q3 		$56.5K Sell
676
-3,963
-85% -$264K ﹤0.01% 2653
2024
Q2 		$256K Buy
4,639
+4,243
+1,071% +$231K ﹤0.01% 1883
2024
Q1 		$27.5K Sell
396
-4,794
-92% -$304K ﹤0.01% 2718
2023
Q4 		$288K Buy
5,190
+4,140
+394% +$187K ﹤0.01% 1801
2023
Q3 		$37.7K Sell
1,050
-9,200
-90% -$317K ﹤0.01% 2812
2023
Q2 		$324K Buy
10,250
+8,786
+600% +$336K 0.01% 1250
2023
Q1 		$45K Buy
1,464
+1,005
+219% +$30.5K ﹤0.01% 2579
2022
Q4 		$14K Sell
459
-3,130
-87% -$71.8K ﹤0.01% 3482
2022
Q3 		$67K Buy
3,589
+1,635
+84% +$31.3K ﹤0.01% 2892
2022
Q2 		$35K Buy
1,954
+1,307
+202% +$16.9K ﹤0.01% 3205
2022
Q1 		$9K Buy
+647
New +$10.8K ﹤0.01% 4423

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Tower Research Capital (TRC)'s ACLX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Arcellx (ACLX) stake by 432% in Q1 2026, buying an estimated $163K and bringing the position to 2,270 shares worth $261K. The position accounts for 0.01% of the portfolio, ranked #1415.

Tower Research Capital (TRC) first reported a position in ACLX in Q1 2022 and has held it in 17 quarters since. The position peaked at $612K in Q4 2024. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Tower Research Capital (TRC) held 2,270 shares of Arcellx worth $261K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,843 Arcellx shares in Q1 2026, an estimated $163K.
  • Arcellx made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1415 holding.
  • Tower Research Capital (TRC) first reported a position in Arcellx in Q1 2022 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Arcellx position peaked at $612K in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.